• About us
• Contact

Advertisement

Organisation › Details

MRC Technology (MRCT)

MRC Technology (www.mrctechnology.org) is an independent life science medical research charity, offering professional services to organisations within the academic, charity, biotechnology and pharmaceutical sectors globally. Services include IP management and research and development for diagnostics, small molecules and therapeutic antibodies. MRC Technology bridges the gap between basic medical research and commercialisation, helping early discoveries progress to clinical application. Four of MRC Technology’s projects have led to approved drugs (Tysabri®, Actemra®, Entyvio®, Keytruda®) and the company has a strong pipeline in development. Please note MRC Technology has been independent from the UK’s Medical Research Council (MRC) since 2000. *

 

	Start	1999-01-01 renamed
	End	2017-06-15 renamed
	Group	LifeArc (GB)
	Today	LifeArc (GB)
	Predecessor	MRC Collaborative Centre
	Successor	LifeArc (GB)
	Industry	IP services
	Industry 2	LIFE SCIENCES
	Region	London, Greater London
	Country	United Kingdom (GB)
	Street	7–12 Tavistock Square Lynton House
	City	WC1H 9LT London
		Address record changed: 2024-01-05
Basic data	Employees	n. a.
		* Document for »About Section«:
		Record changed: 2020-09-05

Advertisement

More documents for LifeArc (GB)

• [1] LifeArc. (5/2/23). "Press Release: Dr Jason Slingsby Joins LifeArc as Chief Business Officer"....
• [2] Maxion Therapeutics Ltd.. (2/15/23). "Press Release: Maxion Therapeutics’ $16 Million Series A to Drive Antibody Development for Previously Untreatable Ion Channel and GPCR-driven Diseases". Cambridge....
• [3] Biocartis Group N.V.. (9/1/20). "Press Release: Biocartis Expands Collaboration with LifeArc". Mechelen & London....
• [4] Kymab Ltd.. (6/24/19). "Press Release: Kymab and LifeArc Enter Strategic Partnership to Discover New Medicines Using Kymab’s IntelliSelect Technologies". Cambridge....
• [5] LifeArc. (5/20/19). "Press Release: LifeArc Monetises Keytruda Royalty Interests to Fund further Research and Investment"....
• [6] LifeArc. (2/27/18). "Press Release: LifeArc Announces £5M Support for Rare Disease Research". London....
• [7] SpringWorks Therapeutics, Inc.. (9/25/17). "Press Release: SpringWorks Therapeutics Launches with $103M in Series A Funding and Rights to Four Clinical Programs". New York, NY....
• [8] LifeArc. (8/30/17). "Press Release: LifeArc and AUTM Forge International Partnership to Provide Training for Scholars in Technology Transfer". London & Gainesville, FL....
• [9] LifeArc. (6/15/17). "Press Release: LifeArc Set to Transform Medical Research Landscape"....
• [10] Biocartis Group N.V.. (6/7/17). "Press Release: MRC Technology and Biocartis Initiate Development of Liquid Biopsy Test for Breast Cancer". London & Mechelen....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.